Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myokardia Inc Cm ST (MYOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first...

MYOK : 56.80 (+2.07%)
Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis Towers Watson Public...

WLTW : 159.62 (+0.49%)
TCBI : 96.45 (+0.26%)
QURE : 34.09 (-4.24%)
ROIC : 19.03 (-0.63%)
GDS : 44.81 (-0.44%)
MYOK : 56.80 (+2.07%)
MyoKardia Announces Pricing of Public Offering of Common Stock

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of...

MYOK : 56.80 (+2.07%)
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO2 and NYHA Classification Improvements

MYOK : 56.80 (+2.07%)
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos,...

MYOK : 56.80 (+2.07%)
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the...

MYOK : 56.80 (+2.07%)
MyoKardia Reports First Quarter 2018 Financial Results

Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT)

MYOK : 56.80 (+2.07%)
MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report...

MYOK : 56.80 (+2.07%)
Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on MBRX, MYOK, NKTR, and NVAX which can be accessed for free by signing up to www.wallstequities.com/registration....

NVAX : 1.43 (+0.70%)
MYOK : 56.80 (+2.07%)
MBRX : 1.75 (+0.57%)
NKTR : 48.73 (-0.71%)
New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliance Resource Partners,...

CDXS : 15.90 (+0.95%)
SFIX : 34.38 (+0.38%)
PAAS : 16.52 (+0.92%)
ARLP : 19.10 (-0.52%)
MYOK : 56.80 (+2.07%)
CHFC : 56.19 (+0.12%)
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment...

MYOK : 56.80 (+2.07%)
MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first...

MYOK : 56.80 (+2.07%)
Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia Pharmaceuticals Inc....

CBPO : 102.46 (+0.67%)
LNDC : 14.50 (+0.35%)
SPNS : 10.28 (+1.58%)
CMTA : 10.90 (+1.96%)
APPF : 65.75 (-0.90%)
MYOK : 56.80 (+2.07%)
Noteworthy Friday Option Activity: MYOK, RBC, INCY

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MyoKardia Inc , where a total of 2,495 contracts have traded so far, representing approximately...

MYOK : 56.80 (+2.07%)
MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

Met Primary Endpoint and Key Secondary Endpoints with Statistical Significance

MYOK : 56.80 (+2.07%)
MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results

Announced Achievement of Primary Endpoint and Additional Key Data from Low-Dose

MYOK : 56.80 (+2.07%)
MyoKardia, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 8, 2018 / MyoKardia, Inc. (NASDAQ: MYOK) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern Time.

MYOK : 56.80 (+2.07%)
MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report...

MYOK : 56.80 (+2.07%)
Today's Research Reports on Stocks to Watch: Endocyte and MyoKardia

NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Endocyte shares saw big gains on Monday after reporting its fourth quarter report and an agreement with ITM Isotopen Technologien. Shares of MyoKardia also...

ECYT : 17.33 (+1.35%)
MYOK : 56.80 (+2.07%)
MyoKardia to Present at the RBC Capital Markets' 2018 Healthcare Conference

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management...

MYOK : 56.80 (+2.07%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.53 , CAKE -0.45 , PLT -0.28 , AEO -0.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed the week with most contracts 3 to 4 cents higher on Friday. Nearby September was up 4.1% since last Friday, with higher closes every day this week. Solid exports and drier weather fueled some bottom picking and short covering acti...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar